mRNA Flu Shot Gets FDA Scrutiny

Moderna’s new mRNA flu shot, mFlusiva, could be a game-changer for seniors—fast, flexible, and built on the same tech that saved us from COVID. With FDA approval looming before flu season hits, this shot promises quicker updates as the virus evolves. But don’t forget the drama: earlier this year, the FDA questioned Moderna’s trial design, though the company countered with solid data showing comparable antibody levels to the high-dose flu vaccine. Still, experts are watching closely—especially for those with weakened immune systems. This panel meeting could be the turning point for flu prevention’s future. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7e682f077f3c4f22